Glucomannan From Acrocomia corumbaensis (Bocaiuva) Attenuates Pain and Inflammation in DSS ‐Induced Colitis via Mucus Barrier Protection
Year: 2026
Type: article
Abstract: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by weight loss, abdominal pain, diarrhoea and rectal bleeding. Polysaccharides have recognized protective and immunoregulatory effects in the gut. This study investigated BFS, a glucomannan extracted from bocaiuva, in dextran sulphate sodium (DSS)-induced colitis. Male and female C57BL/6J mice received 3% DSS and BFS (1, 10, or 100 mg/kg, orally) for 7 days. Disease activity index (DAI) was monitored daily, while abdominal mechanical hypersensitivity and behavioural tests were assessed using von Frey filaments, elevated plus maze and nest-building tests. Colons were collected for histological and biochemical analyses. BFS did not prevent DAI increase, but at 100 mg/kg reduced mechanical hypersensitivity. BFS prevented histopathological damage, inflammatory infiltration and alterations in mucosal architecture. BFS also reduced MPO, IL-1β, TNF-α, IFN-γ and NFκB phosphorylation. Additionally, BFS preserved mucin content and MUC-2 expression, with QCM-D analysis corroborating its mucoadhesive potential. In males, BFS improved behavioural welfare parameters. Although BFS did not improve clinical signs, it preserved the mucus barrier and exerted anti-inflammatory and analgesic effects, supporting its therapeutic potential in UC.
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,150
Awards: G9001367035, G9001367293
OpenAlex ID: W7225638615
